Episode 62: Drug pricing partisanship, tech's march into health care, and Tinder for clinical trials
Has drug price reform already stalled? How far has tech come in medicine? And should there be an app for that?
May 16, 2019•23 min
The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
Episode 61: Pharma felonies, cardiac CRISPR, and a strange day at the FDA
Are law-breaking pharma executives the new mob bosses? Can genome editing preventing heart attacks? And can the FDA regulate drug prices?
May 09, 2019•25 min
Episode 60: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms
Is Biogen bracing for a fight? What does Jack Daniels have to do with immunotherapy? And will "micro-dosing" light the way to actual therapies?
May 02, 2019•22 min
Episode 59: When scientists get mad online, for-profit cancer care, & the perils of naming a startup
Who gets to be "influential"? Should you be skeptical of for-profit hospitals? And should George Lucas fire his attorneys?
Apr 25, 2019•22 min
Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print
Who gets to "play God"? Can old technologies learn new tricks? And what does "drug price" even mean?
Apr 18, 2019•22 min
Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst
How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?
Apr 11, 2019•25 min
Episode 56: Cheaper insulin, the next Juul, and diagnosing disease with sound
What if pharma just charged less for drugs? Can speaking three syllables reveal whether you're depressed? And why is Snoop Dogg selling erectile dysfunction pills on TV?
Apr 04, 2019•29 min
Episode 55: The fate of Bristol-Myers-Celgene, the tragedy of SIDS, and health tech's challenges
Why can't investors think for themselves? How do parents cope with inexplicable tragedy? And is tech prepared for the toughest parts of health care?
Mar 28, 2019•27 min
Episode 54: Another big Alzheimer’s failure, postpartum progress, and Long Island shores
Should Alzheimer's researchers just give up on amyloid plaques? What will a new drug mean for new moms with postpartum depression? And which coastal region of Long Island is superior?
Mar 21, 2019•31 min
Episode 53: How startups stop, the new FDA boss, and Theranos on the big screen
Who deserves credit for a new gene therapy? How do you push stop on a startup? And what does MC Hammer have to do with Theranos?
Mar 14, 2019•32 min
Episode 52: Every conceivable angle of Scott Gottlieb's FDA resignation
Why is Scott Gottlieb quitting the FDA? Who will replace him? And what's the proper elastane content of a skinny jean?
Mar 07, 2019•28 min
Episode 51: CEOs at the Senate, merger mania, and sleuthing startups
Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce "Gonzalez"?
Feb 28, 2019•26 min
Episode 50: A big scoop on opioid marketing
What did an opioid patriarch say under oath? Why did everyone want to know so badly? And how might it shape the conversation around the opioid crisis?
Feb 22, 2019•13 min
Episode 49: Painkiller racketeering, the limits of genetic tests, and pharma's day on the Hill
Is pharma about to have its Big Tobacco moment? Are we overestimating human genetics? And can sales reps rap? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Boston Globe reporter Jonathan Saltzman joins us to discuss the case against Insys Therapeutics, the maker of a powerful painkiller now accused of running a nationwide racketeering scheme. Then Dr. Laura Esserman of the University of California, San Francisco, comes on to break down t...
Feb 21, 2019•24 min
Episode 48: The AI hype machine, ketamine's future, and the rocky path ahead for NASH
When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?
Feb 14, 2019•24 min
Episode 47: A bad day for bold biotech, campaign 2020, and where do drugs come from?
Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?
Feb 07, 2019•26 min
Episode 46: Another Alzheimer's setback, crypto for biotech, and a blessing of unicorns
Is the drug industry wrong about Alzheimer's disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?
Jan 31, 2019•25 min
Episode 45: CRISPR upheaval, Celgene's chutzpah, and canine genomics
Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog?
Jan 24, 2019•25 min
Episode 44: FDA furloughs, '80s pop radio, and video game therapeutics
Is the FDA going broke? Can video games be drugs? And when did "Flashdance" come out?
Jan 17, 2019•24 min
Episode 43: A people's history of J.P. Morgan
Do drug developers tip well? Is biotech safe for 6-year-olds? And what's a Cable Car Cosmo?
Jan 10, 2019•15 min
Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring
Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?
Jan 03, 2019•22 min
Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta
What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?
Dec 20, 2018•27 min
Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests
Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?
Dec 13, 2018•23 min
Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history
Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?
Dec 06, 2018•23 min
Episode 38: Your guide to the #CRISPRbabies controversy
What does it mean to edit a person? Has science run afoul of basic ethics? And what's the time difference to Hong Kong?
Nov 29, 2018•24 min
Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts
Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?
Nov 15, 2018•26 min
Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug
Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?
Nov 08, 2018•23 min
Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence
Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does "folie à deux" mean?
Nov 01, 2018•26 min
Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma
Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does "positive" even mean, really?
Oct 25, 2018•22 min
Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy
Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe?
Oct 18, 2018•25 min
Hosted on Megaphone by Spotify
For the best experience, listen in Metacast app for iOS or Android